000			03004cam a2200349Ii 4500
001			95792
003			ES-MaUEC
005			20230102112721.0
006			m o d
007			cr cnu|||unuuu
008			170411s2017 si o 000 0 eng d
020			_a9789811035098 _q(electronic bk.)
020			_a9811035091 _q(electronic bk.)
020			_z9789811035081
020			_z9811035083
040			_aN$T _cN$T _dN$T _dGW5XE _dYDX _dOCLCF _dUAB _dOCLCO _dESU _dAZU _dUPM _dOCLCO _dIOG _dOCLCO _dVT2 _dOTZ _dOCLCQ _dOCLCO _dU3W _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aRE661.D5 _b2017 EB
100	1		_aStewart, Michael W., _eautor
245	1	0	_aDiabetic retinopathy : _bcurrent pharmacologic treatment and emerging strategies _cMichael W. Stewart, MD.
264		1	_aSingapore _bAdis _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_a1. Diabetes and Diabetic Retinopathy: Overview Of A World-Wide Epidemic -- 2. The Diabetic Retina: Anatomy and Pathophysiology -- 3. Treatment of Diabetic Retinopathy: A Historical Perspective -- 4. Targeting Vascular Endothelial Growth Factor -- 5. Corticosteroids: Targeting Multiple Cytokines and Chemokines -- 6. Current Treatment Recommendations -- 7. Vitreolysis: Targeting the Vitreoretinal Interface -- 8. Investigational Medications -- 9. Safety Considerations of Pharmacotherapy -- 10. Socioeconomic Cost of Diabetic Retinopathy and Therapy.
520	3		_aA well-illustrated and comprehensive analysis of the treatment of diabetic retinopathy, this book covers current treatment options and guidelines, whilst also providing a detailed discussion of emerging therapeutic targets. Existing therapeutic options are covered in depth, with a major focus on anti-vascular endothelial growth factor drugs and sustained release corticosteroids, including a review of trial results supporting current treatment guidelines. The use of agents off-label is also discussed. Controversial topics are discussed in detail with an emphasis on helping the reader make informed decisions, particularly when treating patients for which several treatment approaches may be appropriate because trial data does not clearly define the best option. Emerging therapeutic areas are evaluated, as work continues to identify agents that produce superior morphologic responses and visual acuity gains by targeting other molecules that contribute to diabetic retinopathy. Promising new drugs, targets and delivery systems are identified, and their development analysed.
650		7	_aRetinopatía diabética _2embne _0(OCoLC)fst00892234 _0 _9144717
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-3509-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95792 _d95792 _x1